Granted Patent B2

US 12,492,183 · App. 18/254,917 · Granted Dec 9, 2025

Inventors: Antonella Converso (Elkins, PA); David N. Hunter (Hatfield, PA); Abdellatif El Marrouni (Ambler, PA); Anthony J. Roecker (Harleysville, PA); Anthony W. Shaw (Harleysville, PA); William D. Shipe (Chalfont, PA); Cheng Wang (Fort Washington, PA); Deping Wang (Sharon, MA); Yunlong Zhang (Valhalla, NY)

Assignee: Merck Sharp & Dohme LLC

C07D401/10A61P31/18C07D239/82C07D403/10

Abstract

Claims (189)

1 . A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is O or S;

R 2 is —H or —C 1-8 alkyl unsubstituted or substituted with 1 to 17 of F;

R 3 is halo or —C 1-8 alkyl unsubstituted or substituted with 1 to 17 of F;

R 4 is —H, halo, or —C 1-8 alkyl;

R 5 is —H or halo;

R 6 is —H or halo; and

R 7 is a 6-membered ring selected from

(a) phenyl and

(b) a heteroaryl of carbon atoms and 1, 2 or 3 nitrogen atoms, wherein one of the nitrogen atoms may optionally be in the form of an N-oxide, wherein the heteroaryl ring is attached by a carbon atom in the ring to the adjacent carbon atom in —C(R 6 )—; and

wherein the 6-membered ring is unsubstituted or substituted with one or more substituents up to the maximum number allowed by valence, independently selected at each occurrence from:

(i) halo, (ii) —CN, (iii) —NR 8a R 9a , (iv) —S(O) 2 NR 8b R 9b , (v) —C(O)NR 8c R 9c ,

(vi) —S(O) 2 C 1-8 alkyl, and (vii) oxo (═O),

(viii) —C 1-8 alkyl unsubstituted or substituted with 1 to 8 substituents independently selected at each occurrence from —OH and halo,

(ix) —O—(C 1-8 alkyl) unsubstituted or substituted with 1 to 8 substituents independently selected at each occurrence from —OH and halo, and

(x) —C 3-6 cycloalkyl unsubstituted or substituted with 2 to 5 substituents independently selected at each occurrence from —OH and halo; and

R 8a , R 8b , R 8c , R 9a , R 9b and R 9c are each independently selected at each occurrence from —H and —C 1-8 alkyl unsubstituted or substituted with 1 to 8 substituents independently selected at each occurrence from —OH and halo.

2 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is (i) —H, or (ii) an alkyl group selected from —C 1-6 alkyl, —C 1-5 alkyl, —C 1-4 alkyl, or —C 1-3 alkyl, wherein the alkyl group is unsubstituted or substituted with one or more of —F up to the maximum number allowed by valence.

3 . The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R 3 is (i) halo or (ii) an alkyl group selected from —C 1-6 alkyl, —C 1-5 alkyl, —C 1-4 alkyl, or —C 1-3 alkyl, wherein the alkyl group is unsubstituted or substituted with one or more of halo up to the maximum number allowed by valence.

4 . The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein R 4 is —H, halo or —C 1-6 alkyl.

5 . The compound of claim 4 or a pharmaceutically acceptable salt thereof, wherein R 5 is —H, F, Cl or Br.

6 . The compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein R 6 is —H, F, Cl or Br.

7 . The compound of claim 6 or a pharmaceutically acceptable salt thereof, wherein R 8a , R 8b , R 8c , R 9a , R 9b and R 9c are each independently selected from —H or —C 1-6 alkyl unsubstituted or substituted with 1 to 6 substituents independently selected at each occurrence from —OH and halo.

8 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein R 1 is O.

9 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein R 1 is S.

10 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is a 6-membered ring selected from phenyl, pyridine, pyridinone, pyridine n-oxide, pyrimidine, pyrimidinone, pyrazine and triazine, unsubstituted or substituted with one or more substituents up to the maximum number allowed by valence, independently selected at each occurrence from:

(i) halo, (ii) —CN, (iii) —NR 8a R 9a , (iv) —S(O) 2 NR 8b R 9b , (v) —C(O)NR 8c R 9c ,

(vi) —S(O) 2 C 1-8 alkyl,

(vii) —C 1-8 alkyl unsubstituted or substituted with 1 to 8 substituents independently selected at each occurrence from —OH and halo,

(viii) —O—(C 1-8 alkyl) unsubstituted or substituted with 1 to 8 substituents independently selected at each occurrence from —OH and halo, and

(ix) —C 3-6 cycloalkyl unsubstituted or substituted with 2 to 5 substituents independently selected at each occurrence from —OH and halo; and

R 8a , R 8b , R 8c , R 9a , R 9b and R 9c are each independently selected at each occurrence from —H and —C 1-8 alkyl unsubstituted or substituted with 1 to 8 substituents independently selected at each occurrence from —OH and halo.

11 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein, R 1 is O or S; R 2 is —H or —C 1-6 alkyl unsubstituted or substituted with 1 to 13 of —F; R 3 is halo or —C 1-6 alkyl; R 4 is —H, -halo or C 1-6 alkyl; R 5 is —H, —F or —Cl; R 6 is —H, —F or —Cl; wherein the 6-membered ring of R 7 is unsubstituted or substituted with one or more substituents up to the maximum number allowed by valence, independently selected at each occurrence from:

(i) halo, (ii) —CN, (iii) —NR 8a R 9a , (iv) —S(O) 2 NR 8b R 9b , (v) —C(O)NR 8c R 9c ,

(vi) —S(O) 2 C 1-6 alkyl, (vii) —C 1-6 alkyl unsubstituted or substituted with 1 to 6 substituents independently selected at each occurrence from —OH and halo, and

(viii) —O—(C 1-6 alkyl) unsubstituted or substituted with 1 to 6 substituents independently selected at each occurrence from —OH and halo; and

R 8a , R 8b , R 8c , R 9a , R 9b and R 9c are each independently selected from —H or —C 1-6 alkyl unsubstituted or substituted with 1 to 6 substituents independently selected at each occurrence from —OH and halo.

12 . The compound of claim 1 having Formula II

or a pharmaceutically acceptable salt thereof.

13 . The compound of claim 12 , or a pharmaceutically acceptable salt thereof, wherein R 3 is halo or —C 1-6 alkyl.

14 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein R 4 is is —H, halo or —C 1-6 alkyl.

15 . The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein R 5 is —H, —F, —Cl or Br.

16 . The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from:

R a is —H, —C 1-6 alkyl or halo;

R b is —H, halo, —CN or —C 1-6 alkyl;

R c is (i) —H, (ii) —C 1-6 alkyl unsubstituted or substituted with —OH, (iii) —OC 1-6 alkyl unsubstituted or substituted with —OH; or (iv) —SO 2 NR 8 R 9 , (v) SO 2 —C 1-3 alkyl or (vi) —C(O)NR 8 R 9 ;

R cn is —H or —C 1-3 alkyl;

R d is —H, —NR 8 R 9 or —C 1-6 alkyl;

R dn is —H or —C 1-3 alkyl; and

R e is —H, halo, —CN or —C(O)NR 8 R 9 .

17 . The compound of claim 1 that is:

(S)-4-(cyclopropylethynyl)-7-((6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((2-oxo-1,2-dihydropyridin-3-yl)methyl)-4-(trifluoromethyl)-

3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((1-methyl-6-oxo-1,6-dihydropyridin-3-yl)methyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((1-methyl-2-oxo-1,2-dihydropyridin-4-yl)methyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-((4-(cyclopropylethynyl)-2-oxo-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinazolin-7-

yl)methyl)-3-fluorobenzenesulfonamide;

(S)-2-amino-4-((4-(cyclopropylethynyl)-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)benzenesulfonamide;

(S)-4-((4-(cyclopropylethynyl)-2-oxo-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinazolin-7-

yl)methyl)benzamide;

(S)-4-((4-(cyclopropylethynyl)-2-oxo-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinazolin-7-

yl)methyl)benzenesulfonamide;

(S)-4-(cyclopropylethynyl)-6-fluoro-7-(4-(methylsulfonyl)benzyl)-4-(trifluoromethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-4-((4-(cyclopropylethynyl)-6-fluoro-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)benzenesulfonamide;

(S)-2-amino-4-((4-(cyclopropylethynyl)-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)pyridin-1-ium 2,2,2-trifluoroacetate;

(S)-2-amino-6-((4-(cyclopropylethynyl)-6-fluoro-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)pyridin-1-ium 2,2,2-trifluoroacetate;

(S)-2-amino-4-((4-(cyclopropylethynyl)-6-fluoro-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)pyridin-1-ium 2,2,2-trifluoroacetate;

(S)-7-((2-amino-5-fluoropyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((2-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)methyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl)methyl)-6-

fluoro-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)methyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl)methyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-((4-(cyclopropylethynyl)-4-(1,1-difluoroethyl)-2-oxo-1,2,3,4-tetrahydroquinazolin-7-

yl)methyl)benzenesulfonamide;

(S)-4-(cyclopropylethynyl)-7-((2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl)methyl)-3-

ethyl-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl)methyl)-3-

ethyl-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-yl)methyl)-3-

isopropyl-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-3-(2,2-difluoroethyl)-7-((2,4-dimethyl-6-oxo-1,6-

dihydropyrimidin-5-yl)methyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-4-(1,1-difluoroethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-7-((2-amino-6-methylpyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-amino-5-chloropyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-amino-5-fluoropyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-6-fluoro-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-6-chloro-4-(cyclopropylethynyl)-3-methyl-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-6-chloro-4-(cyclopropylethynyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-amino-5-fluoropyrimidin-4-yl)methyl)-6-chloro-4-(cyclopropylethynyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-6-methyl-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-amino-5-methylpyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((6-aminopyridin-2-yl)methyl)-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-7-((6-amino-3-fluoropyridin-2-yl)methyl)-4-(cyclopropylethynyl)-4-(trifluoromethyl)-

3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-amino-5-fluoropyridin-4-yl)methyl)-4-(cyclopropylethynyl)-4-(trifluoromethyl)-

3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-6-fluoro-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-3-methyl-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-6-fluoro-3-methyl-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-2-((4-(cyclopropylethynyl)-6-fluoro-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)-5-(hydroxymethyl)pyridin-1-ium 2,2,2-trifluoroacetate;

(S)-4-(cyclopropylethynyl)-6-fluoro-7-((5-(2-hydroxyethoxy)pyridin-2-yl)methyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-cyano-2-((4-(cyclopropylethynyl)-6-fluoro-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)-5-(2-hydroxyethoxy)pyridine 1-oxide;

(S)-4-((4-(cyclopropylethynyl)-2-thioxo-4-(trifluoromethyl)-1,2,3,4-tetrahydroquinazolin-7-

yl)methyl)benzenesulfonamide;

(S)-7-((6-amino-5-(hydroxymethyl)pyridin-2-yl)methyl)-4-(cyclopropylethynyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((6-amino-5-(hydroxymethyl)pyrazin-2-yl)methyl)-4-(cyclopropylethynyl)-6-fluoro-

4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-4-(1,1-difluoroethyl)-6-

fluoro-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-amino-6-chloropyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((4-amino-1,3,5-triazin-2-yl)methyl)-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-2-amino-4-((4-(cyclopropylethynyl)-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)nicotinonitrile;

(S)-4-(cyclopropylethynyl)-6-fluoro-7-(pyrazin-2-ylmethyl)-4-(trifluoromethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-2-amino-4-((4-(cyclopropylethynyl)-6-fluoro-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)nicotinonitrile;

(S)-4-(cyclopropylethynyl)-6-fluoro-7-(pyridin-2-ylmethyl)-4-(trifluoromethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-7-((6-aminopyrazin-2-yl)methyl)-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-2-amino-4-((4-(cyclopropylethynyl)-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)nicotinamide;

(S)-4-((4-(cyclopropylethynyl)-6-fluoro-2-oxo-4-(trifluoromethyl)-1,2,3,4-

tetrahydroquinazolin-7-yl)methyl)nicotinonitrile;

(S)-4-(cyclopropylethynyl)-6-fluoro-7-(pyridin-4-ylmethyl)-4-(trifluoromethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-7-((2-amino-5-fluoropyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-4-(1,1-

difluoroethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((2-aminopyrimidin-4-yl)methyl)-4-(cyclopropylethynyl)-6,8-difluoro-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((R)-(2-aminopyrazin-4-yl)fluoromethyl)-4-(cyclopropylethynyl)-6-fluoro-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-7-((S)-(2-aminopyrazin-4-yl)fluoromethyl)-4-(cyclopropylethynyl)-6-fluoro-4-

(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((3-hydroxypyrazin-2-yl)methyl)-4-(trifluoromethyl)-3,4-

dihydroquinazolin-2(1H)-one;

(S)-6-chloro-4-(cyclopropylethynyl)-7-((2,4-dimethyl-6-oxo-1,6-dihydropyrimidin-5-

yl)methyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

(S)-4-(cyclopropylethynyl)-7-((2-(hydroxymethyl)-4-methyl-6-oxo-1,6-dihydropyrimidin-5-

yl)methyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one;

or a pharmaceutically acceptable salt thereof.

18 . A pharmaceutical composition comprising an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19 . The pharmaceutical composition of claim 18 further comprising an effective amount of one or more compatible HIV antiviral gents selected from nucleoside or nucleotide HIV reverse transcriptase inhibitors, nucleoside or nucleotide reverse transcriptase translocation inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV fusion inhibitors, HIV entry inhibitors, HIV maturation inhibitors, post-attachment inhibitors and latency reversing agents.

20 . A method for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or ARC in a human subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

21 . A method for eliciting GAG-POL dimerization in HIV-infected cells in a human subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

22 . A method for selectively killing HIV infected GAG-POL expressing cells in a human subject which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

23 . A method for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells in a human subject which comprises administering to the human subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

24 . A method for augmenting the suppression of HIV viremia in a human subject whose viremia is being suppressed by administration of one or more compatible HIV antiviral agents, which comprises additionally administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

25 . The method of claim 24 further comprising administering to the human subject an effective amount of one or more additional compatible HIV antiviral agents selected from nucleoside or nucleotide HIV reverse transcriptase inhibitors, nucleoside reverse transcriptase translocation inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV fusion inhibitors, HIV entry inhibitors, HIV maturation inhibitors, post-attachment inhibitors and latency reversing agents.

Assignments (2)

Continuity (2)

References Cited (12)